贝伐珠单抗治疗难治性颅内脑膜瘤的作用:单中心经验与文献系统综述
本文报告单中心收治的23例复发脑膜瘤患者接受贝伐珠单抗单药治疗的经验,并系统复习文献。首次注射后中位无进展生存期为7个月,6个月无进展生存率为57%;系统综述显示贝伐珠单抗控制肿瘤生长的能力有限,但作者认为其疗效优于文献中报告的其他全身治疗。
要点
- 23例难治性复发脑膜瘤患者接受贝伐珠单抗单药治疗,首次注射后中位无进展生存期为7个月。
- 首次注射后6个月无进展生存率为57%。
- 系统综述显示贝伐珠单抗控制肿瘤生长的能力有限,作者认为仍需进一步研究以确定可从贝伐珠单抗获益的患者特征。
核心结论
- 贝伐珠单抗用于治疗难治性脑膜瘤患者,其疗效虽有限,但优于文献中报告的其他全身治疗。
- 作者认为需进一步研究以确定可从贝伐珠单抗获益的患者特征。
研究设计与样本
- 单中心病例系列:纳入2000年1月至2020年9月在本院诊断为复发脑膜瘤并接受贝伐珠单抗单药治疗的患者,共23例,初次诊断时中位年龄为55岁。
- 同时进行文献系统综述。
主要发现
- 接受贝伐珠单抗治疗时,WHO I级脑膜瘤2例、WHO II级10例、WHO III级11例。
- 首次贝伐珠单抗注射后中位无进展生存期为7个月,6个月无进展生存率为57%。
- 2例患者因高血压和失语停止贝伐珠单抗治疗。
- 文献系统综述显示贝伐珠单抗控制肿瘤生长的能力有限。
局限性
- 原文指出文献中关于贝伐珠单抗疗效的资料稀少。
- 原文结论指出贝伐珠单抗疗效有限,并认为需进一步研究以确定可从贝伐珠单抗获益的患者特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Meningiomas account for over 30% of all primary brain tumors. While surgery can be curative for these tumors, several factors may lead to a higher likelihood of recurrence. For recurrent meningiomas, bevacizumab may be considered as a therapeutic agent, but literature regarding its efficacy is sparse. Thus, we present a systematic review of the literature and case series of patients from our institution with treatment-refractory meningiomas who received bevacizumab. METHODS: Patients at our institution who were diagnosed with recurrent meningioma between January 2000 and September 2020 and received bevacizumab monotherapy were included in this study. Bevacizumab duration and dosages were noted, as well as progression-free survival (PFS) after the first bevacizumab injection. A systematic review of the literature was also performed. RESULTS: Twenty-three patients at our institution with a median age of 55 years at initial diagnosis qualified for this study. When bevacizumab was administered, 2 patients had WHO grade I meningiomas, 10 patients had WHO grade II meningiomas, and 11 patients had WHO grade III meningiomas. Median PFS after the first bevacizumab injection was 7 months. Progression-free survival rate at 6 months was 57%. Two patients stopped bevacizumab due to hypertension and aphasia. Systematic review of the literature showed limited ability for bevacizumab to control tumor growth. CONCLUSION: Bevacizumab is administered to patients with treatment-refractory meningiomas and, though its effectiveness is limited, outperforms other systemic therapies reported in the literature. Further studies are required to identify a successful patient profile for utilization of bevacizumab.
引用
- Alexander AY, Onyedimma C, Bhandarkar AR, et al. The role of bevacizumab for treatment-refractory intracranial meningiomas: a single institution's experience and a systematic review of the literature. Acta Neurochir (Wien). 2022. PMID: 36117185. doi:10.1007/s00701-022-05348-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。